⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5556956 | 0.81 | — | — | |
| SCHEMBL4806141 | 0.70 | — | — | |
| SCHEMBL7863609 | 0.70 | — | — | |
| SCHEMBL4391911 | 0.70 | — | — | |
| SCHEMBL791507 | 0.70 | — | — | |
| SCHEMBL2752470 | 0.67 | — | — | |
| SCHEMBL3396070 | 0.66 | — | — | |
| SCHEMBL4247194 | 0.65 | — | — | |
| SCHEMBL5196281 | 0.65 | — | — | |
| SCHEMBL15017856 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9840508-B2 | N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders | OGED SA (BE) | 2017-12-12 | — | — | US | claimed |
| US-9422299-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists | EUROSCREEN SA (BE) | 2016-08-23 | — | — | US | claimed |
| EP-4313973-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Acesion Pharma ApS (DK) | 2024-02-07 | — | — | EP | disclosed |
| CN-112272670-B | Di-ring derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| EP-4193399-A2 | ELECTRONIC DEVICE | Merck Patent GmbH (DE) | 2023-06-14 | — | — | EP | disclosed |
| CN-112272670-A | Bicyclic derivative-containing inhibitor, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2021-01-26 | — | — | CN | disclosed |
| EP-3241249-A1 | COMPOSITIONS COMPRISING AT LEAST ONE POLYMER AND AT LEAST ONE METAL COMPLEX AND TO ELECTROLUMINESCENT DEVICES CONTAINING SAID COMPOSITIONS | Merck Patent GmbH (DE) | 2017-11-08 | — | — | EP | disclosed |
| EP-3210249-A1 | MATERIALS FOR ELECTRONIC DEVICES | Merck Patent GmbH (DE) | 2017-08-30 | — | — | EP | disclosed |
| EP-3210248-A1 | MATERIALS FOR ELECTRONIC DEVICES | Merck Patent GmbH (DE) | 2017-08-30 | — | — | EP | disclosed |
| EP-3181553-A1 | QUINAZOLINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | Arromax Pharmatech Co., Ltd. (CN) | 2017-06-21 | — | — | EP | disclosed |
| EP-2928894-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF THE SODIUM IODIDE SYMPORTER | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2015-10-14 | — | — | EP | disclosed |
| WO-2014083529-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF THE SODIUM IODIDE SYMPORTER | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-06-05 | — | — | WO | disclosed |
| US-7414048-B2 | 4,5-dihydro-isoxazole derivatives and their pharmaceutical use | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-08-19 | — | — | US | disclosed |
| US-7081463-B2 | Hydroxy alkyl substituted 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-07-25 | — | — | US | disclosed |
| US-6875764-B1 | Urea and thiourea compounds useful for treatment of coccidiosis | NEW PHARMA RESEARCH SWEDEN AB (SE) | 2005-04-05 | — | — | US | disclosed |
| US-6583141-B1 | T cell mediated rheumatic diseases | JANSSEN PHARMACEUTICA, N.V. (BE) | 2003-06-24 | — | — | US | disclosed |